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ABSTRACT
 
Objective:
 
To compare how cyclooxygenase-2 (COX-2)
users with and without cardiovascular (CV) risks responded
to the withdrawal of rofecoxib on September 30, 2004.
 
Methods:
 
The data, from a pharmacy claims database, con-
sisted of patients who ﬁlled at least one prescription for a
COX-2 agent in the 6 months before September 30, 2004
(n 
 
=
 
 32,898) or September 30, 2003 for the control cohort
(n 
 
=
 
 37,930). Baseline drug utilization was used to determine
comorbidities, and CV risk status was assessed with surro-
gate pharmacy markers. The ﬁrst difference estimator was
used to compare changes in utilization after September 30,
2004 with changes in utilization in a control cohort of
patients who were treated with COX-2 over a similar time
frame in 2003/2004.
 
Results:
 
The reduction in COX-2 utilization depended on
baseline CV risk status. Among celecoxib and valdecoxib
users, patients without CV risks reduced their utilization of
COX-2, as measured by days of supply, by between 16.2%
and 22.7%. The reduction was 32% for patients with one
CV risk marker and 55.8% for patients with three or more
markers, a proxy for the severity of CV risk. The correspond-
ing ﬁgures for rofecoxib users were 47.5% (no CV risk),
55.4% (one marker) and 64.8% (three or more markers).
 
Conclusions:
 
Our results suggest that patients and physi-
cians used newly available information about COX-2 inhib-
itor agents and their side effects to reduce treatment. They
also provide support for the notion that patients and provid-
ers were discriminating in their response to new information
as a signiﬁcant proportion of patients remained on treatment
after extensive publicity concerning potential risks.
 
Keywords:
 
 cardiovascular risk, cyclooxygenase-2 (COX-2)
inhibitors, rofecoxib withdrawal, utilization.
 
Introduction
 
The adverse events observed in the Adenomatous
Polyp Prevention on Vioxx (APPROVe) study con-
vinced the maker of rofecoxib (Merck, White Plains,
NY) to voluntarily withdraw the drug from the market
on September 30, 2004. In the months after the with-
drawal, new evidence raised more concerns about the
cardiovascular (CV) safety of the entire cyclooxygen-
ase-2 (COX-2) inhibitors class of agents [1]. The Ade-
noma Prevention with Celecoxib study and a study of
the safety of valdecoxib after coronary-artery bypass
grafting (CABG) surgery both linked COX-2 drugs to
CV events [2,3].
How COX-2 inhibitors contribute to the risk of CV
events is not yet known with certainty, but researchers
postulate that COX-2 inhibitors increase the risk for
thrombotic events because they lack the antiplatelet
effect that occurs with COX-1 inhibition (COX-1 inhi-
bition explains the cardioprotective effects of aspirin,
for instance) and because they decrease prostacyclin
(PGI
 
2
 
) production, a hormone made by normal artery
wall cells that has vasodilating and antiaggragatory
properties [4,5]. The increase in CV risk may be due to
the unopposed action of thromboxane A
 
2
 
 (whose pro-
duction depends on COX-1), which causes platelet
aggregation, vasoconstriction, and smooth muscle pro-
liferation [4,6] thus increasing the risk of ischemic
events.
Mounting evidence conﬁrming the association
between CV events and long-term COX-2 utilization,
along with heightened public concerns about the safety
of this drug class, led to serious criticisms of the Food
and Drug Administration (FDA) drug approval proc-
ess and of postmarketing safety monitoring [7–11]. On
April 7, 2005 the FDA reacted with drastic measures:
It requested the withdrawal of valdecoxib (Pﬁzer, New
York, NY) from the US market along with stronger
label warnings for celecoxib (Pﬁzer) and nonselective
nonsteroidal anti-inﬂammatory drugs (NSAIDs)
regarding CV and gastrointestinal side effects [12].
These actions, however, failed to satisfy the propo-
nents of a complete withdrawal of all COX-2 inhibi-
tors from the market [13].
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In the current climate of public health concerns
about an entire class of agents and because the debate
on regulatory oversight often downplays the ability of
patients and physicians to voluntarily alter treatment,
it is important to understand the impact of the
rofecoxib withdrawal (and subsequent events) on clin-
ical practice. This research relies on observed changes
in COX-2 use to assess changes in patient behavior
and physician prescription patterns. It assesses how
patients altered their treatments and if those with CV
risks altered their treatments more dramatically than
similar patients without CV risks.
 
Methods
 
Data
 
Data for this retrospective analysis were provided by
a large national pharmacy beneﬁt management
(PBM) organization. They included information
about individual pharmacy claims, drug beneﬁt
design, and health insurance characteristics for a
period stretching from January 2003 to March 2005
for commercially insured patients and their depend-
ents. Two cohorts of patients were identiﬁed for this
study (Fig. 1). The ﬁrst cohort—hereafter referred
to as treatment cohort, or 2004 cohort—consists of
patients who ﬁlled at least one prescription for a
COX-2 inhibitor agent (rofecoxib, celecoxib, or val-
decoxib) between September 30, 2004 and Septem-
ber 30, 2004. The second cohort of patients—the
control cohort, or 2003 cohort—consists of patients
who ﬁlled at least one prescription for a COX-2
between September 30, 2003 and September 30,
2003. Both cohorts were followed for 6 months
after the withdrawal/index date, from September 30,
2004 for the treatment cohort and September 30,
2003 for the control cohort. In both cohorts,
patients had a 3-month washout period before their
initial COX-2 prescription. Patients were continu-
ously eligible for a whole year starting in March of
2003 or 2004.
COX-2 and nonselective NSAID utilization was
recorded for the 6 months before September 30 and
the 5 months after October 30 (2004 for the treatment
cohort and 2003 for the control cohort). Thirty days
between September 30 and October 30 were removed
from analysis to give patients enough time to adjust to
the withdrawal. There were 32,898 patients in the
treatment cohort and 37,930 in the control cohort.
 
Risk Identiﬁcation
 
The cornerstone of this research is the identiﬁcation of
patients who have CV risks. Because we have access to
only pharmacy claims, this identiﬁcation is based on
surrogate pharmacy markers that provide an indica-
tion of the type and frequency of treatment for CV dis-
ease. The assessment of CV risks is based on the
National Cholesterol Education Program Expert Panel
on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (NCEP Adults Treatment
Panel III 2002) [14]. Patients are at risk if they are cur-
rently suffering from coronary heart disease (CHD) or
have conditions that are associated with coronary
events (CHD risk equivalent) [14]. Most of the drugs
used to treat CHD or CHD risk equivalent were
included in the CV risk markers, with a special condi-
tion imposed on antihypertensives and statins. This
condition is based on the 10-year risk assessment using
Framingham scoring. Drugs used to treat hypercholes-
terolemia—mainly statins, the ﬁrst-line therapy—and
to treat hypertension–angiotensin converting inhibi-
tors, angiotensin receptor blockers, beta-blockers, cal-
cium channel blockers, and diuretics [15]—were added
to the list of CV risk markers only if the patients took
both antihypertensives and statins to ensure that they
had the two CV risk factors required by Framingham.
Individuals with a claim in any of the following four
groups are categorized as having high CV risk: 1)
claim for oral antidiabetes agent or insulin; 2) claim
for antiplatelet agent; 3) claim for a nitrate; and 4)
claim for antihypertensive agent and claim for a statin.
Patients with none of these markers were classiﬁed as
low CV risk. These surrogate pharmacy markers do
not include nonprescription drugs like aspirin because
they are usually not captured in our database. COX-2
users were further divided into high (or chronic) users
and low (or intermittent) users. High users were
deﬁned as those with at least three COX-2 prescrip-
tions in the baseline period and at least 15 days of
COX-2 supply in the month preceding September 30.
This deﬁnition allows us to single out the patients who
are the most susceptible to adverse effects caused by
COX-2 inhibitor treatment. This division, between
patients with low and high baseline COX-2 utilization,
allows us to compare and contrast the intensity of
response in these two groups.
We separated rofecoxib users from celecoxib and
valdecoxib users for analysis purposes. This separation
 
Figure 1
 
Deﬁnition of treatment and control cohorts.
Treatment cohort 
Control cohort 
10/30/03
Time 
4002/33002/3
Index date 
9/30/03Baseline 
period
Post-9/30
period
10/30/04
Time 
5002/34002/3
Withdrawal
9/30/04Baseline 
period
Post-9/30
period
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creates comparable subgroups: Patients who used
celecoxib or valdecoxib in the identiﬁcation period
had the option to remain on the same drug in the post-
September 30, 2004 period, whereas rofecoxib users
had to switch to a different medication. The intrinsic
difﬁculty of switching therapy—patients on rofecoxib
presumably liked this medication better than other
drugs  in  the  same  class—may  be  a  confounder  in
the comparison of postwithdrawal utilization rates.
Valdecoxib  was  withdrawn  after  the  end  of the
study period and did not therefore require a separate
analysis.
The use of proton pump inhibitors (PPI) and H2-
receptor antagonists during the prewithdrawal period
was also recorded to control for GI-related utilization
relevant to the withdrawal decision.
 
Outcomes
 
Three outcomes were deﬁned: days of supply of COX-
2, number of COX-2 prescriptions, and average dose
per day of supply per prescription. All the prescrip-
tions ﬁlled between March 30 and September 30
(preindex date) and from October 30 to March 1
(postindex date) were summed for days of supply.
Note that prescriptions ﬁlled between September 30
and October 30 was not added to the count, to elim-
inate the period of adjustment, or transition, to the
new regime. The same approach was used for the sum
of prescriptions. Finally, average dose per day of sup-
ply per prescription was computed as strength (in mg)
times the number of tablets, divided by days of supply,
averaged over all prescriptions of one drug. This var-
iable was not computed for rofecoxib.
 
Covariates
 
In addition to surrogate pharmacy markers for CV
risks and binary variables for H2/PPI agents, covari-
ates also included baseline characteristics. First, we
deﬁned predictors related to the patients: age, sex,
region, and health status as determined by the RxRisk
system, a risk assessment system that classiﬁes patients
into comorbidity categories depending on their medi-
cation use [16] (refer to Appendix A for details). We
also deﬁned predictors related to health insurance: for-
mulary types, health plan sizes, and average copay.
There are three types of formulary, ranked from least
to most restrictive: open, incentive, and closed. A
closed formulary does not cover nonformulary drugs,
an incentive formulary covers nonformulary drugs but
at a higher patient copay, and an open formulary cov-
ers nonformulary drugs at the same copay. The health
plan size variables are divided into three categories as
well, depending on the total number of enrollees: 1) up
to 50,000 for small plans; 2) from 50,000 to 200,000
for medium plans; and 3) more than 200,000 for large
plans. Average copay represents the mean out-of-
pocket cost per COX-2 prescription in the baseline
period. Additional analyses, for patients who initiated
treatment with either celecoxib or valdecoxib, were
performed on change in drug formulary status (pre-
ferred vs. nonpreferred) and change in average copay.
 
Statistical Model and Underlying Assumptions
 
Empirical evaluation must address the issue of the
counterfactual—in this case, what would have hap-
pened if the withdrawal of rofecoxib had not occurred.
Clearly, the problem is that we cannot observe this
hypothetical outcome [17,18]. The critical issue for
unbiased estimation is therefore to ﬁnd a cohort of
patients, a control group, similar to the treatment
cohort, which can be used to create the counterfactual
[17]. In the longitudinal analysis we use, the relevant
characteristic of these cohorts is the change in utiliza-
tion between pre- and postindex date.
This research relies on a control group of COX-2
users similar to, but treated a year earlier than, the
COX-2 users affected by the event of September 2004.
A ﬁxed-effect panel estimator was used to quantify the
effect of rofecoxib withdrawal on utilization. Both
cohorts are included in a two-period ﬁxed effect panel
written as follows: 
 
y
 
it
 
 
 
=
 
 
 
x
 
it
 
 
 
β
 
 
 
+
 
 
 
α
 
i
 
 
 
+
 
 
 
ε
 
it
 
 for t 
 
=
 
 1 and 2
and patients i, where 
 
y
 
it
 
 is drug utilization, 
 
x
 
it
 
 includes
all the predictors as well as a treatment binary variable,
 
α
 
i
 
 is the individual effect (i.e., all observed and unob-
served time-invariant individual characteristics), and 
 
ε
 
it
 
is  the  stochastic  error.  The  ﬁrst  difference  estimator
is the ordinary least squares (OLS) estimator of the
change in predictors on the change in outcomes—the
difference—between period 1 (prewithdrawal) and
period 2 (postwithdrawal). This data transformation
eliminates the individual effect, allowing the ﬁrst dif-
ference estimator to control for all stable characteris-
tics, even if correlated with treatment. This estimator
recovers the average effect of the withdrawal by remov-
ing the effect of all stable observed and unobserved
patient characteristics and common macro effects that
could introduce biases in our estimation [19].
Unbiased estimation therefore requires: 1) that con-
trol and treatment cohorts be sufﬁciently similar at
baseline to be expected to have the same utilization
trajectories in the absence of withdrawal; and 2) that
conditional on predictors, temporary changes in utili-
zation (i.e., at most a few months) be the same in the
treatment cohort and the control cohort. In other
words, estimation could be biased if there had been a
temporary “shock,” like a temporary disruption in
drug supply, affecting COX-2 utilization in the control
cohort [17]. Our results (see Results, Table 1) indicate
that both cohorts are similar in baseline characteristics
and utilization, allowing us to maintain the assump-
tion of similar utilization trajectories. To determine
whether utilization patterns had changed substantially
and erratically during the prewithdrawal study period,
we ﬁrst reviewed the literature for any recommenda-
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tions to alter COX-2 prescribing patterns. The conclu-
sion is clearly that no new information emerged on the
CV risk associated with COX-2 between March 2003
and September 2004 [4,20]. Second, we performed a
simple time-series analysis of COX-2 utilization across
all the health plans contracting with the PBM supply-
ing our data (results not shown here, available from
authors). This analysis shows that utilization for each
COX-2 was either slowly increasing or constant
between March 2003 and September 2004, without
any spikes or dips. Consequently, utilization trajecto-
ries—the change in utilization over time—are likely to
be identical between control and treatment cohorts.
 
Results
 
Before withdrawal, a nearly equal number of patients
in the treatment cohort were on celecoxib (13,237)
and rofecoxib (13,212). In the control cohort, a higher
proportion of patients were on rofecoxib (16,880)
than on celecoxib (14,887). The valdecoxib popula-
tion remained approximately constant in the treatment
(6,449) and control cohort (6,163).
There are some small differences in baseline char-
acteristics between the cohorts (Table 1). Patients in
the treatment cohort are 1.6 years older than those in
the control cohort and 1% more likely to be female.
The average baseline copays are almost identical in
both cohorts ($24.2 in the treatment vs. $24.0 for the
control cohort) even though the proportion of COX-2
drugs that have a preferred status, or are in the
formulary, was quite different (54.4% treatment vs.
74.4%). Finally, treatment cohort patients are also
more likely to suffer from hypertension/hyperlipi-
demia, asthma, or epilepsy but less likely to suffer from
diabetes or gastric acid disorders.
Baseline COX-2 utilization and CV risk status are
similar in the treatment and control cohorts (Table 2).
More patients in the control cohort were low or inter-
mittent users (fewer than three claims between March
30 and September 30 or less than 15 days of supply in
the month before September 30) than in the treatment
cohort but the difference is small. Differences in the
proportion of high or chronic users, both with and
without CV risks, are not statistically signiﬁcant. Less
than 10% of the patients are both high users and have
a CV risk status.
A comparison of utilization before and after
rofecoxib withdrawal (Table 3) reveals that both aver-
age days of COX-2 supply and average number of
 
Table 1
 
Sample baseline characteristics
 
Treatment
(2004–05)
Control
(2003–04)
Difference,
 
P
 
-value
 
†
 
Age (year) 57.3 55.7
 
< 
 
0.0001
Sex (% female) 65.4 64.4 0.0094
Average COX-2 copay ($) 24.2 24.0 0.42
% in formulary 54.4 76.4
 
< 
 
0.0001
% in large plans 57.9 39.9
 
< 
 
0.0001
% in medium plans 12.5 30.5
 
< 
 
0.0001
% in small plans 29.7 29.6 0.9379
RxRisk categories* (% of patients; 
conditions with more than 5% of all patients)
Anxiety and tension 14.6 15.0 0.2804
Asthma 9.6 9.1 0.0019
Cardiac disease 26.1 25.3
 
< 
 
0.0001
Coronary/peripheral vascular
disease
5.6 5.1 0.0101
Depression 15.6 16.8 0.0840
Diabetes 9.5 14.1
 
< 
 
0.0001
Epilepsy 9.2 7.7
 
< 
 
0.0001
Gastric acid disorder 13.1 15.0 0.0003
Hypertension/
hypercholesterolemia
33.4 31.3
 
< 
 
0.0001
 
*RxRisk categories. Refer to Appendix A for details.
 
†
 
Chi-square for proportion and 
 
t
 
-test for means.
COX-2, cyclooxygenase-2.
 
Table 2
 
Baseline frequency of COX-2 utilization and frequency of cardiovascular (CV) risks
 
Treatment 
(2004–05)
Control
(2003–04)
Difference,
 
P
 
-value*
Celecoxib and valdecoxib users 19,686 21,050
Frequency (percentage)
Low use without CV risk marker
 
†
 
12,011 (61.0%) 13,567 (64.5%)
 
<
 
0.0001
Low use and at least one CV risk marker
 
†
 
4,513 (22.9%) 4,336 (20.6%)
 
<
 
0.0001
High use without CV risk marker
 
†
 
2,006 (10.2%) 2,033 (9.7%) 0.073
High use and one CV risk marker
 
†
 
716 (3.6%) 705 (3.3%) 0.818
High use and two CV risk markers
 
†
 
315 (1.6%) 298 (1.4%) 0.509
High use and three or more CV risk markers
 
†
 
115 (0.6%) 111 (0.5%) 0.372
Rofecoxib users 13,212 16,880
Frequency (percentage)
Low use without CV risk marker
 
†
 
8,750 (66.2%) 11,410 (67.6%) 0.0123
Low use and at least one CV risk marker
 
†
 
3,175 (18.8%) 2,634 (19.9%) 0.014
High use without CV risk marker
 
†
 
1,215 (9.2%) 1,578 (9.3%) 0.652
High use and one CV risk marker
 
†
 
386 (2.9%) 474 (2.8%) 0.716
High use and two CV risk markers
 
†
 
171 (1.3%) 189 (1.1%) 0.206
High use and three or more CV risk markers
 
†
 
56 (0.4%) 54 (0.3%) 0.159
 
*Chi-square.
 
†
 
Low use: patients had 
 
<
 
 3 COX-2 claims between March 30 and September 30 or 
 
<
 
 15 days of supply in month before September 30. High use: patients had 
 
≥ 
 
3 COX-2 claims
between March 30 and September 30 and 
 
≥ 
 
15 days of supply in month before September 30. CV risk marker: a claim for at least one of the following drugs categories over
the 6 months before September 30: 1) antidiabetes drugs; 2) antiplatelet agents; 3) nitrates; or 4) antihypertensives and statins.
COX-2, cyclooxygenase-2.
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prescriptions ﬁlled fell dramatically among high users
with CV risk, the patients who may be the most at risk
of COX-2 related CV events. Among celecoxib and
valdecoxib users, the average number of claims
decreased signiﬁcantly—by 2.3 prescriptions in the
treatment cohort compared with 0.7 in the control
cohort. A similar trend is observed for days of supply
(
 
−
 
66.5 days in the treatment group vs. 
 
−
 
27.8 control)
and for both measures among rofecoxib users. Utiliza-
tion change in nonspeciﬁc NSAIDs follows a different
pattern. Celecoxib and valdecoxib users slightly
reduced their use of other NSAIDs after the with-
drawal whereas rofecoxib users increased theirs sub-
stantially. These ﬁgures indicate that some rofecoxib
users switched to nonspeciﬁc NSAID treatment rather
than starting another COX-2. They are, however,
likely to understate the shift to nonspeciﬁc NSAIDs as
lower strength, purchased over the counter, are usually
not captured in our data. Note that Table 3 presents
unadjusted average values.
The proportion of COX-2 users—patients who
ﬁlled at least one prescription—did not substantially
decrease among celecoxib and valdecoxib users after
the rofecoxib withdrawal (Table 4). Among high users
of celecoxib and valdecoxib, the post-September pro-
portion of users went from 82.2% to 77.3% among
patients without CV risk and from 84.6% to 79.1%
among patients with CV risk. There is a far greater
drop in the proportion of rofecoxib users from 81.8%
to 38.7% among patients without CV risk and from
84.4% to 33.0% among patients with CV risk.
The analysis performed with the ﬁrst difference esti-
mator clearly demonstrates the negative effect of the
withdrawal on utilization (Table 5). These ﬁgures
show the change in utilization trajectories (i.e., the dif-
ference in differences) between the treatment and con-
trol cohorts, not the change in utilization levels within
any single cohort. On average, celecoxib and val-
decoxib users reduced their COX-2 utilization by
22.2% in days of supply and 17.3% in number of pre-
scriptions. More importantly, the magnitude of the
reduction varies greatly among patients depending on
their baseline utilization and CV risk status. Among
low users, patients with CV risks reduced their utili-
zation more than patients without CV risks. The same
pattern emerges among high users: Patients without
 
Table 3
 
Average utilization among high or chronic users with cardiovascular (CV) risk—unadjusted*
 
Baseline (184 days) Postindex date (142 days) 
Treatment
(2004–05)
Control
(2003–04)
Treatment
(2004–05)
Control
(2003–04)
Celecoxib and valdecoxib users
Total number COX-2 claims/number of claims per day 4.2/0.023
 
†
 
4.1/0.023 1.9/0.013
 
†
 
3.4/0.024
 
†
 
Total days of supply for COX-2/days of supply for COX-2 per day 113.7/0.625
 
†
 
112.8/0.620
 
†
 
47.2/0.332
 
†
 
85.0/0.599
 
†
 
Total number nonspeciﬁc NSAID claims/number nonspeciﬁc NSAID claims per day 0.7/0.004
 
†
 
0.6/0.003
 
†
 
0.5/0.004
 
†
 
0.5/0.004
 
†
 
Total days of supply for nonspeciﬁc NSAID/days of supply for nonspeciﬁc NSAID
per day
17.4/0.096
 
†
 
15.9/0.087
 
†
 
10.8/0.076
 
‡
 
11.5/0.081
 
‡
 
Rofecoxib users
Total number COX-2 claims/number of claims per day 4.1/0.023 4.1/0.023 0.9/0.006
 
†
 
3.4/0.024
 
†
 
Total days of supply for COX-2/days of supply for COX-2 per day 116.9/0.642
 
†
 
112.6/0.619
 
†
 
21.7/0.153
 
†
 
81.8/0.576
 
†
 
Total number nonspeciﬁc NSAID claims/number nonspeciﬁc NSAID claims per day 0.1/0.001
 
†
 
0.1/0.001
 
†
 
0.6/0.004
 
†
 
0.2/0.001
 
†
 
Total days of supply for nonspeciﬁc NSAID/days of supply for nonspeciﬁc NSAID
per day
2.5/0.014
 
‡
 
2.8/0.015
 
‡
 
13.4/0.094
 
†
 
4.4/0.031
 
†
 
*High use: patients had 
 
≥ 
 
3 COX-2 claims between March 30 and September 30 and 
 
≥ 
 
15 days of supply in month before September 30; CV risk: a claim for at least one of the
following drugs categories over the 6 months before September 30: 1) antidiabetes drugs; 2) antiplatelet agents; 3) nitrates; or 4) antihypertensives and statins.
 
†
 
Difference between treatment and control signiﬁcant at 
 
P
 
 
 
<
 
 0.01.
 
‡
 
t
 
-test, difference between treatment and control signiﬁcant at 
 
P
 
 
 
<
 
 0.05.
COX-2, cyclooxygenase-2; NSAID, nonsteroidal anti-inﬂammatory drug.
 
Table 4
 
Proportion of users after withdrawal, all patients, unadjusted
 
Celecoxib and valdecoxib users,
% with at least one COX-2 claim*
Rofecoxib users, % with at least one 
COX-2 claim*
Treatment
(2004–05)
Control
(2003–04)
Treatment
(2004–05)
Control
(2003–04)
Low use and no CV risk
 
†
 
28.1
 
‡
 
31.1
 
‡
 
12.4
 
‡
 
31.4
 
‡
 
Low use and CV risk
 
†
 
34.9
 
‡
 
49.0
 
‡
 
15.3
 
‡
 
37.4
 
‡
 
High use and no CV risk
 
†
 
77.3
 
‡
 
82.2
 
‡
 
38.7
 
‡
 
81.8
 
‡
 
High use and CV risk
 
†
 
79.1‡ 84.6‡ 33.0‡ 84.4‡
*Users are patients who ﬁlled at least one prescription for a COX-2 after September 2003 or 2004.
†Low use: patients had < 3 COX-2 claims between March 30 and September 30 or < 15 days of supply in month before September 30. High use: patients had ≥ 3 COX-2 claims
between March 30 and September 30 and ≥ 15 days of supply in month before September 30; CV risk: a claim for at least one of the following drugs categories over the 6 months
before September 30: 1) antidiabetes drugs; 2) antiplatelet agents; 3) nitrates; or 4) antihypertensives and statins.
‡Chi-square, difference between treatment and control signiﬁcant at P < 0.01.
COX-2, cyclooxygenase-2; CV, cardiovascular.
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CV risks reduced their utilization of COX-2, as meas-
ured by days of supply, by 22.7% among celecoxib
and valdecoxib users and by 47.5% among rofecoxib
users. For patients with one CV risk marker, these
ﬁgures rise to 32% among celecoxib and valdecoxib
users and 55.4% among rofecoxib users. In addition, a
greater number of CV risk markers, a proxy for the
severity of CV risk, was related to a greater reduction
in COX-2 utilization. Patients with three or more
markers (diabetes, antiplatelet, and nitrate, for
instance) lowered their utilization by 55.8% (celecoxib
and valdecoxib users) and 64.8% (rofecoxib users).
The reduction in the number of prescriptions has
the same magnitude as the reduction observed in days
of supply in each of the utilization and CV risk
subgroups.
Finally, note that the reduction in COX-2 utiliza-
tion is more pronounced in patients who used
rofecoxib at baseline than in the other patients, pre-
sumably because when they were forced to discontinue
rofecoxib, some abandoned treatment completely and
others switched to nonspeciﬁc NSAIDs.
The small reduction in the proportion of users
(Table 4)  stands  in  contrast  to  the  signiﬁcant  drop
in actual quantity used (Table 5). The comparison of
these results suggests that, particularly among
celecoxib and valdecoxib users, patients were far more
likely to reduce their utilization of COX-2s than to
stop treatment altogether immediately after the
withdrawal.
An  analysis  of  average  dosage  before  and  after
the withdrawal determined whether providers had
changed their prescription practices. This analysis was
limited to celecoxib and valdecoxib users to ensure
that drug regimens before and after withdrawal were
comparable. The unit of analysis is the average daily
dose strength. There was virtually no change in pre-
scription strength after the withdrawal, suggesting that
most of the treatment alteration occurred through a
reduction in the number of prescriptions instead of a
change in dosage. Before the withdrawal, the average
daily dose was 231.6 mg for celecoxib and 18.3 mg for
valdecoxib. After the withdrawal, the average daily
dose remained unchanged for celecoxib (231.7 mg)
and dropped slightly for valdecoxib (16.2 mg).
Discussion
The withdrawal of rofecoxib in September 2004 had
a dramatic impact not only on patients who had been
using rofecoxib but also on patients who had been
using celecoxib and valdecoxib. In this sample,
patients who were using celecoxib and valdecoxib in
2004 reduced their COX-2 utilization, in terms of days
of supply, by an average of 22.2% compared with the
2003 control cohort. Patients on rofecoxib reduced
their utilization by an average of 55.2%. These aver-
ages, however, conceal a wide difference in reduction
rates among patients. Patients at risk for CV events
decreased their utilization far more than patients who
were not at risk. Among low users of celecoxib and
valdecoxib, CV risk was associated with a 38.9%
reduction in utilization after the withdrawal compared
with only 16.2% for patients without CV risk. Among
low users of rofecoxib, patients with CV risk reduced
use by 78.9% and those with no risk reduced use by
50.0%.
These results are replicated among high or chronic
COX-2 users. This group of patients is important
because they are far more exposed to potential adverse
effects caused by their treatment. Patients on celecoxib
and valdecoxib with no CV risk markers decreased
their COX-2 utilization by 22.7% (patients on
rofecoxib, by 47.5%) whereas those with at least one
CV risk marker reduced their utilization by 40% or
more (60.3% for patients on rofecoxib). Furthermore,
Table 5 Effect of rofecoxib withdrawal on COX-2 utilization, ﬁrst difference estimator, treatment cohort relative to control cohort
Change in days of supply
(percent change)*,†
Change in number of COX-2
prescriptions (percent change)*,†
Celecoxib and
valdecoxib users Rofecoxib users
Celecoxib and
valdecoxib users Rofecoxib users
Average for all patients −10.4 (−22.2%) −19.3 (−55.2%) −0.4 (−17.3%) −0.7 (−40.0%)
Low use‡ without CV risk§ −5.0 (−16.2%) −13.2 (−50.0%) −0.2 (−13.2%) −0.5 (−34.4%)
Low use with at least one CV risk −11.3 (−38.9%) −19.1 (−78.9%) −0.4 (−26.1%) −0.6 (−49.1%)
High use|| without CV risk −24.4 (−22.7%) −49.5 (−47.5%) −0.9 (−23.3%) −1.9 (−49.7%)
High use with at least one CV risk and PPI or H2 agents −42.0 (−40.0%) −62.0 (−60.3%) −1.6 (−38.9%) −2.6 (−65.6%)
High use with one type of drugs for CV risk −34.6 (−32.0%) −58.2 (−55.4%) −1.4 (−31.2%) −2.4 (−60.5%)
High use with two types of drugs for CV risk −38.3 (−35.7%) −70.8 (−65.3%) −1.5 (−34.7%) −2.7 (−65.4%)
High use with three types¶ of drugs or more for CV risk −60.0 (−55.8%) −61.1 (−64.8%) −2.6 (−57.8%) −2.9 (−74.5%)
*First difference estimator: compares the rate of change between control and treatment group.
†All coefﬁcient signiﬁcant at P < 0.01.
‡Low use: patients had < 3 COX-2 claims between March 30 and September 30 or < 15 days of supply in month before September 30.
§CV risk marker: a claim for at least one of the following drugs categories over the 6 months before September 30: 1) antidiabetes drugs; 2) antiplatelet agents; 3) nitrates; or
4) antihypertensives and statins.
||High use: patients had ≥ 3 COX-2 claims between March 30 and September 30 and ≥ 15 days of supply in month before September 30.
¶COX-2 users with three or four risk markers were combined because the number of users with four markers was insufﬁcient for analysis.
COX-2, cyclooxygenase-2; CV, cardiovascular.
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the greater the number of CV risk markers, a proxy for
the severity of CV risk, the greater the drop in utiliza-
tion. Among celecoxib and valdecoxib users, one CV
risk marker was associated with a 40% reduction in
utilization and three or more markers were associated
with a 55.8% reduction. Rofecoxib users with similar
risk proﬁles reduced their utilization by an even greater
amount 55.4% for one marker and 64.8% for three
markers.
The strong and discriminating reactions to the with-
drawal of rofecoxib indicate that the withdrawal gave
a clear signal to providers and patients. Our results
suggest that a number of patients, on their own or with
their physicians’ help, used newly available informa-
tion about COX-2 inhibitor agents and their side
effects to adjust their treatments, reducing their expo-
sure to CV events. Patients suffering from heart disease
were far more likely to stop COX-2 treatment than
other patients, and a number of them switched to non-
speciﬁc NSAIDs. In addition, higher CV risks were
associated with a greater drop in COX-2 use. It is also
important to note that the changes in COX-2 utiliza-
tion described here were not accompanied by similar
changes in the strength of prescription dispensed: The
average dose per day of supply per prescription did not
change after September 2004.
Even with the dramatic change in utilization noted
above, and in spite of the wide circulation of informa-
tion about the potential side effects of COX-2 treat-
ment, a large number of patients treated for CV
conditions chose to remain on COX-2 medications. It
is possible that after being assessed for treatment
impact and potential dangers, these patients/providers
decided that the positive effects outweighed the risks.
There is therefore a need to focus additional research
on the health of patients with CV disease who stayed
on this class of medication knowing its risk proﬁle.
Meanwhile, patients, providers, and payers need to be
mindful of ongoing research developments on COX-2s
and continue to respond prudently in the patients’
greatest interest.
Study Limitation
The major limitation of this study is that we can only
identify patients with CV risks if they received drug
treatment for their condition. We cannot identify
patients who had been diagnosed yet were not receiv-
ing treatment, and these were grouped with the
patients without CV risks. But how similar are these
patients? Can we generalize our results to all patients
who suffered from heart disease? Some answers can be
found in our observations. In the control cohort,
change in utilization follows the same pattern of in
patients with CV risk and patients without (available
from Correspondence). In the treatment cohort, there
was not difference in baseline utilization between
patients with CV risks and patients (available from
Correspondence). These observations suggest that
patients diagnosed with heart disease but not treated
followed a trajectory very similar to that of patients we
identiﬁed as having CV risks. Because patients who
had drug surrogate markers for CV risks reduced their
utilization more than other cohorts, it is reasonable
to assume that those who were only diagnosed but
not treated also reduced their utilization more than
patients without CV risks. Consequently, there is a
likely exaggeration of the withdrawal effect in patients
labeled as having no CV risks.
This does not, however, imply that our estimates of
the withdrawal effect are biased; our observations sug-
gest that both types of patients follow a very similar
trajectory, and so our results should be generalizable.
Additional research is nonetheless needed to conﬁrm
this proposition.
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Appendix A: Drugs Used to Classify Patients 
into Comorbidity Categories
Comorbidity categories Drugs used for classiﬁcation
Anxiety and tension Benzodiazepine and barbiturates
Asthma Inhaled bronchodilators and 
leukotriene inhibitors
Depression Antidepressants
Diabetes Insulin and oral hypoglycemics
Gastric acid disorder H2 antagonist and proton pump 
inhibitors
Cardiac disease Nitrates, digoxin, antiarrythmics, and 
loop diuretics
Coronary/peripheral vascular 
disease
Anticoagulant and antiplatelet agents
Hypertension/
hypercholesterolemia
Beta-blockers, calcium channel 
blockers, thiazides, potassium-
sparing agents, combination 
antihypertensives, other 
antihypertensives, ACE and 
angiotensin II inhibitors.
